Whole-body diffusion-weighted imaging in lymphoma

Cancer Imaging

Volumn 10, Issue SPEC. ISS. A, 2010, Pages

  Lin, C ^a,b   Itti, E ^a   Luciani, A ^a   Haioun, C ^a   Meignan, M ^a   Rahmouni, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

FDG PET CT; Lymphoma; Response assessment; Staging; Whole body DWI

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; LYMPHOMA; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; WHOLE BODY IMAGING;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79955735378     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.9029     Document Type: Review

References (40)

1. Thoeny HC, De Keyzer F. Extracranial applications of diffusionweighted magnetic resonance imaging. Eur Radiol 2007; 17: 1385-93. doi:10.1007/s00330- 006-0547-0. PMid:17206421. (Pubitemid 46767586)
2. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505.
3. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35. doi:10.2214/AJR.06.1403. PMid:17515386. (Pubitemid 46866868)
4. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006; 16: 1468-77. doi:10.1007/ s00330-005-0133-x. PMid:16557366. (Pubitemid 43871818)
5. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2009; 72: 381-7. doi:10.1016/j.ejrad.2008.09.034. PMid:-18995981.
6. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009; 251: 134-46. doi:10.1148/radiol.2511080128. PMid:19251938.
7. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusionweighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239: 122-30. doi:10.1148/radiol.2383041384. PMid:16493012.
8. Lin G, Ng KK, Chang CJ, et al. Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging-initial experience. Radiology 2009; 250: 784-92. doi:10.1148/radiol.2503080874. PMid:19244045.
9. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-8. doi:10.1148/radiol.2261011904. PMid:12511671. (Pubitemid 36163910)
10. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005 12; 102: 5524-9. (Pubitemid 40530291)
11. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-8. doi:10.1016/S0140-6736(02)09520-X. (Pubitemid 34874724)
12. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001-8. doi:10.2214/AJR.06.0601. PMid:17377036. (Pubitemid 46496932)
13. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010; 20: 1703-14. doi:10.1007/s00330-010-1734-6. PMid:20179939.
14. Nakayama T, Yoshimitsu K, Irie H, et al. Usefulness of the calculated apparent diffusion coefficient value in the differential diagnosis of retroperitoneal masses. J Magn Reson Imaging 2004; 20: 735-42. doi:10.1002/jmri.20149. PMid:15390151. (Pubitemid 39313752)
15. Sumi M, Ichikawa Y, Nakamura T. Diagnostic ability of apparent diffusion coefficients for lymphomas and carcinomas in the pharynx. Eur Radiol 2007; 17: 2631-7. doi:10.1007/s00330-007-0588-z. PMid:17429643.
16. Toh CH, Castillo M, Wong AM, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008; 29: 471-5. doi:10.3174/ajnr.A0872. PMid:18065516. (Pubitemid 351424059)
17. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22: 275-82. (Pubitemid 39264807)
18. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 2008; 18: 1937-52. doi:10.1007/s00330-008-0968-z. PMid:18446344.
19. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 2007; 6: 211-24. doi:10.2463/ mrms.6.211. PMid:18239358.
20. Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography/-computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007; 21: 209-15. doi:10.1007/s12149-007-0010-6. PMid:17581719. (Pubitemid 47387439)
21. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008; 248: 643-54. doi:10.1148/ radiol.2482072039. PMid:18539889.
22. Stecco A, Romano G, Negru M, et al. Whole-body diffusionweighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med 2009; 114: 1-17. doi:10.1007/s11547-008-0348-4. PMid:19082787.
23. Kwee TC, Quarles van Ufford HM, Beek FJ, et al. Wholebody MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009; 44: 683-90. doi:10.1097/ RLI.0b013e3181afbb36. PMid:19724232.
24. Kwee TC, Fijnheer R, Ludwig I, et al. Whole-body magnetic resonance imaging, including diffusion-weighted imaging, for diagnosing bonerow involvement in malignant lymphoma. Br J Haematol 2010; 149: 628-30. doi:10.1111/j.1365-2141.2010.-08093.x. PMid:20128795.
25. Takahara T, Kwee T, Kibune S, et al. Whole-body MRI using a sliding table and repositioning surface coil approach. Eur Radiol 2010; 20: 1366-73. doi:10.1007/s00330-009-1674-1. PMid:-19997846.
26. Lin C, Luciani A, Itti E, et al. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20: 2027-38. doi:10.1007/s00330-010-1758-y. PMid:20309558.
27. Li S, Xue HD, Li J, et al. Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J 2008; 23: 138-44. doi:10.1016/ S1001-9294(09)60028-6.
28. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800. (Pubitemid 27227433)
29. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475-81. (Pubitemid 28112964)
30. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004; 232: 823-9. doi:10.1148/radiol.2323030985. PMid:15273335. (Pubitemid 39100269)
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin-s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
32. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med 2004; 45: 1509-18. (Pubitemid 47618505)
33. Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 2004; 14: 1829-41. (Pubitemid 39386632)
34. Punwani S, Taylor SA, Bainbridge A, et al. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology 2010; 255: 182-90. doi:10.1148/ radiol.09091105. PMid:20308456.
35. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-8. doi:10.1200/JCO.2006.08.2305. PMid:17242397. (Pubitemid 350002965)
36. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86. doi:10.1200/JCO.2006.09.2403. PMid:17242396. (Pubitemid 350002966)
37. Huang MQ, Pickup S, Nelson DS, et al. Monitoring response to chemotherapy of non-Hodgkin-s lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR in biomedicine 2008; 21: 1021-9. doi:10.1002/nbm.1261. PMid:18988250.
38. Ballon D, Watts R, Dyke JP, et al. Imaging therapeutic response in human bonerow using rapid whole-body MRI. Magn Reson Med 2004; 52: 1234-8. doi:10.1002/mrm.20291. PMid:15562475. (Pubitemid 39612810)
39. Juan CJ, Chang HC, Hsueh CJ, et al. Salivary glands: echo-planar versus PROPELLER Diffusion-weighted MR imaging for assessment of ADCs. Radiology 2009; 253: 144-52. doi:10.1148/radiol.2531082228. PMid:19789257.
40. De Foer B, Vercruysse JP, Bernaerts A, et al. Middle ear cholesteatoma: non-echo-planar diffusion-weighted MR imaging versus delayed gadolinium-enhanced T1-weighted MR imaging-value in detection. Radiology 2010; 255: 866-72. doi:10.1148/radiol-.10091140. PMid:20501723.